Etiology and pathogenetic mechanisms of optic disc swelling with visual loss: An interdisciplinary prospective pilot study of 102 cases

Ophthalmologica

Volumn 213, Issue 1, 1999, Pages 40-47

  Stammen, Johannes ^a   Unsöld, Renate ^a,b   Arendt, Gabriele ^a   Vester, Ernst G ^a   Heering, Peter ^a   Freund, Hans Joachim ^a   Strauer, Bodo Eckehard ^a   Grabensee, Bernd ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b Augenarztpraxis   (Germany)

Author keywords

Anterior ischemic optic neuropathy; Etiology and pathogenetic mechanisms; Optic disc swelling; Optic neuritis; Optic neuropathy with disc edema

Indexed keywords

ADULT; AGED; ARTICLE; BLOOD CLOTTING DISORDER; DIABETES MELLITUS; EMBOLISM; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; PAPILLEDEMA; PATHOGENESIS; PROSPECTIVE STUDY; VASCULAR DISEASE; VISUAL IMPAIRMENT;

ADULT; AGED; BLINDNESS; CARDIOVASCULAR DISEASES; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; OPTIC DISK; OPTIC NEURITIS; OPTIC NEUROPATHY, ISCHEMIC; PAPILLEDEMA; PILOT PROJECTS; PROSPECTIVE STUDIES; RETINAL HEMORRHAGE; RISK FACTORS; VISUAL ACUITY; VISUAL FIELDS;

EID: 0032890211     PISSN: 00303755     EISSN: None     Source Type: Journal    
DOI: 10.1159/000027392     Document Type: Article

References (35)

1. Levin LA: Clarifying the treatment of nonarteritic anterior ischemic optic neuropathy. JAMA 1995;273:666-667.
2. Menzi J, Körner F: Systemic corticosteroid therapy in non-arteritic ischemic optic neuropathy. Klin Monatsbl Augenheilk 1992;200: 349-353.
3. The Ischemic Optic Neuropathy Decompression Trial Research Group: Optic nerve decompression surgery for nonarteritic ischemic optic neuropathy (NAION) is not effective and may be harmful. JAMA 1995;273:625-632.
4. Wolf S, Schulte-Strake U, Bertram B, Schulte K, Arend O, Reim M: Haemodilution therapy in patients affected by acute anterior ischaemic optic neuropathy. Ophthalmologe 1993;90:21-26.
5. Beck RW, Cleary PA, Anderson MM Jr, Keltner JL, Shults WT, Kaufman DI, Buckley EG, Corbett JJ, Kupersmith MJ, Miller NR, Savino PJ, Guy JR, Trobe JD, McCrary JA III, Smith CH, Chrousos GA, Thompson HS, Katz BJ, Brodsky MC, Goodwin JA, Atwell CW, Optic Neuritis Study Group: A randomized, controlled trial of corticosteroids in the treatment of acute optic neuritis. N Engl J Med 1992;326: 581-588.
6. Miller NR: Anterior ischemic optic neuropathy; in Miller NR (ed): Walsh and Hoyt's Clinical Neuro-Ophthalmology, ed 4. Baltimore, Williams & Wilkins, 1982, pp 212-226.
7. Miller NR: Cerebrovascular Diseases: Causes of Embolism; in Miller NR (ed): Walsh and Hoyt's Clinical Neuro-Ophthalmology, ed 4. Baltimore, Williams & Wilkins, 1991, pp 2271-2287.
8. Boghen DR, Glaser JS: Ischaemic optic neuropathy: The clinical profile and natural history. Brain 1975;98:689-708.
9. Rizzo JF III, Lessell S: Optic neuritis and ischemic optic neuropathy: Overlapping clinical profiles. Arch Ophthalmol 1991;109:1668-1672.
10. Kupersmith MJ, Burde RM, Warren FA, Klingele TG, Frohman LP, Mitnick H: Autoimmune optic neuropathy: Evaluation and treatment. J Neurol Neurosurg Psychiatry 1988;51: 1381-1386.
11. Unsöld R: Optic neuropathy in systemic inflammatory disease and vasculitis: A poorly recognized early sign. Ophthalmologe 1994;91: 251-262.
12. Cerebral Embolism Task Force: Cardiogenic brain embolism. Arch Neurol 1986;43:71-84.
13. Cerebral Embolism Task Force: Cerebral embolism. Chest 1986;89(suppl):82-98.
14. Cerebral Embolism Task Force: Cardiogenic brain embolism: The second report of the Cerebral Embolism Task Force. Arch Neurol 1989; 46:727-743.
15. D'Olhaberriague L, Hernández-Vidal A, Molina L, Soler-Singla L, Marrugat J, Pons S, Moral A, Pou-Serradell A: A prospective study of atrial fibrillation and stroke. Stroke 1989;20: 1648-165 2.
16. Ezekowitz MD, James KE, Kazarian SM, Davenport J, Broderick JP, Gupta SR, Thadani V, Meyer ML, Bridgers SL: Silent cerebral infarction in patients with nonrheumatic atrial fibrillation. Circulation 1995;92:2178-2182.
17. Flegel KM, Hanley J: Risk factors for stroke and other embolic events in patients with non-rheumatic atrial fibrillation. Stroke 1989;20: 1000-1004.
18. Hart RG, Foster JW, Luther MF, Kanther MC: Stroke in infective endocarditis. Stroke 1990; 21:695-700.
19. Kittner SJ, Sharkness CM, Price TR, Plotnick GD, Dambrosia JM, Wolf PA, Mohr JP, Hier DB, Kase CS, Tuhrim S: Infarcts with a cardiac source of embolism in the NINCDS Stroke Data Bank: Historical features. Neurology 1990;40:281-284.
20. Leather RA, Kerr CR: Atrial fibrillation in absence of overt cardiac disease; in Falk R, Podril PJ (eds): Atrial Fibrillation: Mechanism and Management. New York, Raven Press, 1992.
21. Schlepper M: Identification of the patients with atrial fibrillation at risk for thromboembolism; in Olsson SB, Allessie MA, Campbell RWF (eds): Atrial Fibrillation: Mechanisms and Therapeutic Strategies. Armonk, Futura Publishing Company, 1994, pp 15-24.
22. Sirna S, Biller J, Skorton DJ, Seabold JE: Cardiac evaluation of the patient with stroke. Stroke 1990;21:14-23.
23. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: The Framingham study. Stroke 1991;22:983-988.
24. Hansen LL, Wiek J, Danisevskis M, Schrader W: Isovolemic hemodilution in non-arteritic ischemic optic neuropathy: First results of a randomized study. Fortschr Ophthalmol 1991; 88:487-489.
25. Sawle GV, James CB, Ross Russell RW: The natural history of non-arteritic anterior ischaemic optic neuropathy. J Neurol Neurosurg Psychiatry 1990;53:830-833.
26. Atrial Fibrillation Investigators: Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation. Arch Intern Med 1994; 154:1449-1457.
27. Conolly SJ, Laupacis A, Gent M, Roberts RS, Cairns JA, Joyner C: Canadian atrial fibrillation anticoagulation (CAFA) study. J Am Coll Cardiol 1991;18:349-355.
28. European Atrial Fibrillation Trial Study Group: Secondary prevention in nonrheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-1265.
29. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B: Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation. The Copenhagen AFASAK Study. Lancet 1989;i:175-179.
30. The Stroke Prevention in Atrial Fibrillation Investigators: Stroke Prevention in atrial fibrillation study: Final results. Circulation 1991;84: 527-539.
31. The Stroke Prevention in Atrial Fibrillation Investigators: Predictors of thromboembolism in atrial fibrillation. Ann Intern Med 1992;116: 1-12.
32. The Stroke Prevention in Atrial Fibrillation Investigators: Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. Lancet 1994;343:687-691.
33. Wheeldon NM: Atrial fibrillation and anticoagulant therapy. Eur Heart J 1995;16:302-312.
34. Acheson JF, Sanders MD: Coagulation abnormalities in ischaemic optic neuropathy. Eye 1994;8:89-92.
35. Homberg M, Tschöpe D, Greber H, Hackländer T, Schwippert B, Gries FA, Mödder U: Optic neuropathy in type-1 diabetes and acetyl-salicylic acid-refractory thrombocyte activation. Dtsch med Wochenschr 1993;118:290-295.